DelveInsight has launched a new report on”Fibrodysplasia Ossificans Progressiva – Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Fibrodysplasia Ossificans Progressiva – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva, historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Fibrodysplasia Ossificans Progressiva Market Report:
- A study stated that the worldwide prevalence of FOP is approximately 1 in 2,000,000.
- As per Delveinsight’s analysis, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva in the seven major markets was found to be 630 in 2019. In the United States, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva was found to be 293 in 2019.
- In EU5 countries, the total diagnosed prevalent cases of Fibrodysplasia Ossificans Progressiva, in 2019, were found to be maximum in Germany with 62 cases followed by France with 50 cases, while the least number of diagnosed prevalent cases of Fibrodysplasia Ossificans Progressiva was found in Spain with 35 cases, in 2019.
- As per the analysis of Delveinsight, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva in Japan was found to be 95, in 2019.
Key benefits of the report:
- Fibrodysplasia Ossificans Progressiva market report covers a descriptive overview and comprehensive insight of the Fibrodysplasia Ossificans Progressiva epidemiology and Fibrodysplasia Ossificans Progressiva market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Fibrodysplasia Ossificans Progressiva market report provides insights on the current and emerging therapies.
- Fibrodysplasia Ossificans Progressiva market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Fibrodysplasia Ossificans Progressiva market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fibrodysplasia Ossificans Progressiva market.
Got queries? Click here to know more about Fibrodysplasia Ossificans Progressiva Market Landscape.
Fibrodysplasia Ossificans Progressiva Overview
Fibrodysplasia ossificans progressiva (FOP) is a disorder in which skeletal muscle and connective tissue, such as tendons and ligaments, are gradually replaced by bone (ossified). This condition leads to bone formation outside the skeleton (extra-skeletal or heterotopic bone) that restricts movement. People with FOP are born with abnormal big toes (hallux valgus) which can be helpful in making the diagnosis. These flare-ups last for several days to months and often result in permanent bone growth in the injured area.
The key player involved in the Fibrodysplasia Ossificans Progressiva market:
- Ipsen
- Keros Therapeutics
- Regeneron Pharmaceuticals
- BioCryst
- And others
The launch of the emerging therapies is expected to significantly impact the Fibrodysplasia Ossificans Progressiva treatment scenario in the upcoming years:-
Drug covered
- Palovarotene and BLU-782
- KER-047
- Garetosmab (REGN2477)
- BCX9250
- And others.
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Fibrodysplasia Ossificans Progressiva Patient Share (%) Overview at a Glance
5. Fibrodysplasia Ossificans Progressiva Market Overview at a Glance
6. Fibrodysplasia Ossificans Progressiva Disease Background and Overview
7. Fibrodysplasia Ossificans Progressiva Epidemiology and Patient Population
8. Country-Specific Patient Population of Fibrodysplasia Ossificans Progressiva
9. Fibrodysplasia Ossificans Progressiva Current Treatment and Medical Practices
10. Unmet Needs
11. Fibrodysplasia Ossificans Progressiva Emerging Therapies
12. Fibrodysplasia Ossificans Progressiva Market Outlook
13. Country-Wise Fibrodysplasia Ossificans Progressiva Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Fibrodysplasia Ossificans Progressiva Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/